across developed and emerging markets to advance wellness, prevention, 
treatments and cures that challenge the most feared diseases of our 
time. Consistent with our responsibility as one of the world's premier 
innovative biopharmaceutical companies, we collaborate with health care 
providers, governments and local communities to support and expand 
access to reliable, affordable health care around the world. For more 
than 150 years, we have worked to make a difference for all who rely on 
us. We routinely post information that may be important to investors on 
our website at 
https://www.globenewswire.com/Tracker?data=ugo-RFdDBnNS8ML1SOK89rToyGH2QbtTq-QbBnwQaKnNJXtDXdNdSoj3Kq3gXh9PZq6QnkTnRagZW8j4gumvSw== 
www.Pfizer.com. In addition, to learn more, please visit us on 
https://www.globenewswire.com/Tracker?data=ugo-RFdDBnNS8ML1SOK89v490rPKJYiJOWYl3uUlwobV2Q9tV-6yozrXpsdqUwacuqewyKneK1--WTP3MEhDWw== 
www.Pfizer.com and follow us on Twitter at 
https://www.globenewswire.com/Tracker?data=g6ep93NoLVZQzvX7FoLn9MLtI2KW-yOU9ZzBX15HzgaHTMCPP3oFH5F_jzsryHu5x_4BCUVRLmaDifOqZCo9XQ== 
@Pfizer and 
https://www.globenewswire.com/Tracker?data=g6ep93NoLVZQzvX7FoLn9DVKNed6kWhACLtbpmdmZsvrKGxAy5Bc10Xip5BvvsF71GJMK8m0DvWwypYBg_4MwBzjsWjocg33JDkkvYFSCI0= 
@Pfizer News, 
https://www.globenewswire.com/Tracker?data=7-22d3D34BFNoBm76Re3eBzdmGfPJPEG2h0eTaRfy9Z3LdTLREMAhgGKu_ggbya7jl7x-5E-LB35Lugd2BXgDA6U5Yv7hk5xoU571USoRc4= 
LinkedIn, 
https://www.globenewswire.com/Tracker?data=nEzocESk5JY7O2L2m-0j9Fwk6ZX3-jkkWIhA1P1wGjr3x2htkPSf2pE04qL3RPpVL4sqf_yrKpdfbUQHmw4JHg== 
YouTube and like us on Facebook at 
https://www.globenewswire.com/Tracker?data=t8k-PN8LGtCOCqvKdJUHb5dvBljYDsDzWWqOHyj1geRqQpN-UgC7snvJ05gyqZ34aKmcl7g04lorPjs7B-_L2HXVZgXm-EOF1tp1SIQGrQI= 
Facebook.com/Pfizer. 
 
   Pfizer Disclosure Notice 
 
   The information contained in this release is as of March 31, 2021. 
Pfizer assumes no obligation to update forward-looking statements 
contained in this release as the result of new information or future 
events or developments. 
 
   This release contains forward-looking information about Pfizer's efforts 
to combat COVID-19, the collaboration between BioNTech and Pfizer to 
develop a COVID-19 vaccine, the BNT162 mRNA vaccine program, the 
Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), (including qualitative 
assessments of available data, potential benefits, expectations for 
clinical trials, the potential of BNT162b2 for adolescents 12 to 15 
years of age, evaluation of BNT162b2 in children 6 months to 11 years 
old, the anticipated timing of regulatory submissions, regulatory 
approvals or authorizations and anticipated manufacturing, distribution 
and supply) involving substantial risks and uncertainties that could 
cause actual results to differ materially from those expressed or 
implied by such statements. Risks and uncertainties include, among other 
things, the uncertainties inherent in research and development, 
including the ability to meet anticipated clinical endpoints, 
commencement and/or completion dates for clinical trials, regulatory 
submission dates, regulatory approval dates and/or launch dates, as well 
as risks associated with preclinical and clinical data (including the 
data outlined in this release), including the possibility of unfavorable 
new preclinical, clinical or safety data and further analyses of 
existing preclinical, clinical or safety data; the ability to produce 
comparable clinical or other results, including the rate of vaccine 
effectiveness and safety and tolerability profile observed to date, in 
additional analyses of the Phase 3 trial and additional studies or in 
larger, more diverse populations following commercialization; the 
ability of BNT162b2 to prevent COVID-19 caused by emerging virus 
variants; the risk that more widespread use of the vaccine will lead to 
new information about efficacy, safety, or other developments, including 
the risk of additional adverse reactions, some of which may be serious; 
the risk that preclinical and clinical trial data (including the data 
outlined in this release) are subject to differing interpretations and 
assessments, including during the peer review/publication process, in 
the scientific community generally, and by regulatory authorities; 
whether and when additional data from the BNT162 mRNA vaccine program 
(including the data outlined in this release) will be published in 
scientific journal publications and, if so, when and with what 
modifications and interpretations; whether regulatory authorities will 
be satisfied with the design of and results from these and any future 
preclinical and clinical studies; whether and when a Biologics License 
Application for BNT162b2 may be filed in the U.S. and whether and when 
other biologics license and/or emergency use authorization applications 
or amendments to any such applications may be filed in particular 
jurisdictions for BNT162b2 or any other potential vaccines that may 
arise from the BNT162 program, and if obtained, whether or when such 
emergency use authorization or licenses will expire or terminate; 
whether and when any applications that may be pending or filed for 
BNT162b2 (including a potential Biologics License Application in the 
U.S. or any requested amendments to the emergency use authorization) or 
other vaccines that may result from the BNT162 program may be approved 
by particular regulatory authorities, which will depend on myriad 
factors, including making a determination as to whether the vaccine's 
benefits outweigh its known risks and determination of the vaccine's 
efficacy and, if approved, whether it will be commercially successful; 
decisions by regulatory authorities impacting labeling or marketing, 
manufacturing processes, safety and/or other matters that could affect 
the availability or commercial potential of a vaccine, including 
development of products or therapies by other companies; disruptions in 
the relationships between us and our collaboration partners or 
third-party suppliers; risks related to the availability of raw 
materials to manufacture a vaccine; challenges related to our vaccine's 
ultra-low temperature formulation, two-dose schedule and attendant 
storage, distribution and administration requirements, including risks 
related to storage and handling after delivery by Pfizer; the risk that 
we may not be able to successfully develop other vaccine formulations; 
the risk that we may not be able to create or scale up manufacturing 
capacity on a timely basis or maintain access to logistics or supply 
channels commensurate with global demand for our vaccine, which would 
negatively impact our ability to supply the estimated numbers of doses 
of our vaccine within the projected time periods as previously 
indicated; whether and when additional supply agreements will be 
reached; uncertainties regarding the ability to obtain recommendations 
from vaccine technical committees and other public health authorities 
and uncertainties regarding the commercial impact of any such 
recommendations; uncertainties regarding the impact of COVID-19 on 
Pfizer's business, operations and financial results; and competitive 
developments. 
 
   A further description of risks and uncertainties can be found in 
Pfizer's Annual Report on Form 10-K for the fiscal year ended December 
31, 2020 and in its subsequent reports on Form 10-Q, including in the 
sections thereof captioned "Risk Factors" and "Forward-Looking 
Information and Factors That May Affect Future Results", as well as in 
its subsequent reports on Form 8-K, all of which are filed with the U.S. 
Securities and Exchange Commission and available at www.sec.gov and 
https://www.globenewswire.com/Tracker?data=ugo-RFdDBnNS8ML1SOK89mIuZAPYhAI3qxu0Wh3rRZt-uPjwpd6ZzYPFUMfjYCUBxNz6akfuhqtAbkElsyUBhA== 
www.pfizer.com. 
 
   About BioNTech 
 
   Biopharmaceutical New Technologies is a next generation immunotherapy 
company pioneering novel therapies for cancer and other serious 
diseases. The Company exploits a wide array of computational discovery 
and therapeutic drug platforms for the rapid development of novel 
biopharmaceuticals. Its broad portfolio of oncology product candidates 
includes individualized and off-the-shelf mRNA-based therapies, 
innovative chimeric antigen receptor T cells, bi-specific checkpoint 
immuno-modulators, targeted cancer antibodies and small molecules. Based 
on its deep expertise in mRNA vaccine development and in-house 
manufacturing capabilities, BioNTech and its collaborators are 
developing multiple mRNA vaccine candidates for a range of infectious 
diseases alongside its diverse oncology pipeline. BioNTech has 
established a broad set of relationships with multiple global 
pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal 
Health, Genentech, a member of the Roche Group, Regeneron, Genevant, 
Fosun Pharma, and Pfizer. For more information, please visit 
https://www.globenewswire.com/Tracker?data=ugo-RFdDBnNS8ML1SOK89l-xz90_mNNPJbuVg9Cbt3L50_iTlrYT9We5tcau-Ld8Jb-LDv2VMCveyc0iDUkH9w== 
www.BioNTech.de. 
 
   BioNTech Forward-looking Statements 
 
   This press release contains "forward-looking statements" of BioNTech 
within the meaning of the Private Securities Litigation Reform Act of 
1995. These forward-looking statements may include, but may not be 
limited to, statements concerning: BioNTech's efforts to combat 
COVID-19; the collaboration between BioNTech and Pfizer to develop a 
COVID-19 vaccine (including a potential second booster dose of BNT162b2 
and/or a potential booster dose of a variation of BNT162b2 having a 
modified mRNA sequence); our expectations regarding the potential 
characteristics of BNT162b2 in our clinical trials and/or in commercial 
use based on data observations to date; the ability of BNT162b2 to 
prevent COVID-19 caused by emerging virus variants; the expected time 
point for additional readouts on efficacy data of BNT162b2 in our 
clinical trials; the nature of the clinical data, which is subject to 
ongoing peer review, regulatory review and market interpretation; the

(MORE TO FOLLOW) Dow Jones Newswires

March 31, 2021 06:45 ET (10:45 GMT)